• GreenLight Biosciences receives approval to initiate Phase I/II clinical trial of Covid-19 mRNA vaccine candidate 

    1 month ago - By Green Light Biosciences

    The Rwanda FDA has given regulatory approval to GreenLight to start a Phase I/II clinical trial of its Covid-19 vaccine candidate in Rwanda. This phase I/II clinical trial is the first step in GreenLight's integrated strategy of bringing a universal Covid-19 mRNA vaccine to market globally. By initiating this first-in-human clinical study in Rwanda, GreenLight is demonstrating its commitment to partner with the people of Africa in bringing advanced health technologies to the continent.
    Kigali, Rwanda, and Lexington, MA February 1, 2022 -GreenLight Biosciences , a public benefit corporation...
    Read more ...